Tirzepatide titrates from a starting dose of 2.5 mg per week through 6 dose levels to a maximum of 15 mg per week — with each increase held for a minimum of 4 weeks before stepping up — and skipping this titration is the single most common cause of the severe nausea, vomiting, and diarrhea that make users discontinue the drug prematurely.
This guide covers everything a tirzepatide user needs after purchase: the full titration schedule, a master unit conversion table for every common vial size and BAC water combination, step-by-step reconstitution ratios for 10 mg, 30 mg, and 60 mg vials, injection site selection, storage and refrigeration rules, alcohol interaction, dietary guidance, microdosing, and troubleshooting for users not seeing weight loss. Every answer applies equally to compounded tirzepatide (lyophilized vials) and brand-name formulations (Zepbound/Mounjaro pre-filled pens) unless otherwise noted. For tirzepatide's mechanism of action and clinical trial data, see the tirzepatide science deep-dive. For how it compares to semaglutide, see the semaglutide vs tirzepatide comparison.
Tirzepatide Titration Schedule — Starting Dose to Maintenance
The FDA-approved titration schedule for tirzepatide (Zepbound) moves through 6 dose levels with a minimum of 4 weeks at each step. Compounded tirzepatide uses the same schedule — the molecule is the same, the titration requirement doesn't change because it came from a compounding pharmacy.
Step | Weekly Dose | Duration | What to Expect |
|---|---|---|---|
1 | 2.5 mg | 4 weeks minimum | Mild appetite reduction; possible GI adjustment (nausea, mild diarrhea) |
2 | 5 mg | 4 weeks minimum | Appetite suppression strengthens; early weight loss becomes noticeable |
3 | 7.5 mg | 4 weeks minimum | Visible body composition changes begin; GI effects may recur briefly |
4 | 10 mg | 4 weeks minimum | Significant appetite control; sustained weight loss trajectory |
5 | 12.5 mg | 4 weeks minimum | Approaching maximum therapeutic effect |
6 | 15 mg | Maintenance | Maximum approved dose; target maintained until goal or physician adjustment |
The starting dose is always 2.5 mg — this is not flexible. The 2.5 mg dose is an initiation dose designed to let the GI tract adapt to GLP-1 and GIP receptor activation. It is not a therapeutic dose — most users see minimal weight loss at 2.5 mg, which is expected. The therapeutic effect builds as you titrate upward.
Maintenance dose is the dose level where target weight loss response is achieved with tolerable side effects. Not every user needs to reach 15 mg. Many stabilize at 10 mg or 12.5 mg. The SURMOUNT-1 trial showed ~22.5% average body weight loss at 72 weeks on the 15 mg dose — but meaningful weight loss occurred at lower doses too.
Microdosing is a community practice where users start below 2.5 mg (for example, 1.0–1.25 mg for the first 1–2 weeks) or extend each titration step to 6–8 weeks instead of 4. This is not in the FDA prescribing information and has no clinical validation, but the underlying logic — lower initial dose produces fewer GI side effects during adaptation — is pharmacologically sound. Users who microdose typically report gentler GI adjustment but slower onset of appetite suppression. For the full cross-compound dosing reference, see the peptide dosage guide. For when to expect results at each stage, see the peptide results timeline.
Tirzepatide Unit Conversion Table — Units to mg at Every Concentration
The answer to "how many units is 2.5 mg of tirzepatide" depends entirely on the concentration of your reconstituted solution — at 5 mg/mL (10 mg vial + 2 mL BAC water) it's 50 units, at 10 mg/mL (30 mg vial + 3 mL) it's 25 units, and at 15 mg/mL (30 mg vial + 2 mL) it's approximately 17 units — and confusing these concentrations is the most common dosing error with compounded tirzepatide.
Why there is no universal "units to mg" conversion: "Units" on a U-100 insulin syringe are volume measurements — 1 unit = 0.01 mL, 100 units = 1.0 mL. They measure how much liquid you draw, not how much drug is in that liquid. The drug amount depends on the concentration (mg/mL) of your reconstituted solution, which depends on how much BAC water you added to the vial.
Master Conversion Table — Find Your Vial Size and BAC Water Volume
10 mg vial:
BAC Water | Concentration | 2.5 mg dose | 5 mg dose | 7.5 mg dose | 10 mg dose |
|---|---|---|---|---|---|
1 mL | 10 mg/mL | 25 units | 50 units | 75 units | 100 units (full vial) |
2 mL | 5 mg/mL | 50 units | 100 units (full syringe) | — | — |
30 mg vial:
BAC Water | Concentration | 2.5 mg dose | 5 mg dose | 7.5 mg dose | 10 mg dose | 12.5 mg dose | 15 mg dose |
|---|---|---|---|---|---|---|---|
2 mL | 15 mg/mL | ~17 units | ~33 units | 50 units | ~67 units | ~83 units | 100 units |
3 mL | 10 mg/mL | 25 units | 50 units | 75 units | 100 units | — | — |
60 mg vial:
BAC Water | Concentration | 2.5 mg dose | 5 mg dose | 7.5 mg dose | 10 mg dose | 12.5 mg dose | 15 mg dose |
|---|---|---|---|---|---|---|---|
3 mL | 20 mg/mL | ~13 units | 25 units | ~38 units | 50 units | ~63 units | 75 units |
6 mL | 10 mg/mL | 25 units | 50 units | 75 units | 100 units | — | — |
How to read this table: find your vial size (left column), then your BAC water volume (second column), then read across to your target dose. The number shown is the syringe units to draw on a U-100 insulin syringe. If you don't see your combination, use the formula: target dose (mg) ÷ concentration (mg/mL) × 100 = units. For a step-by-step walkthrough of the calculation, see the dose calculator or use the tirzepatide calculator tool.
Example: you have a 30 mg vial and added 3 mL of BAC water. Your concentration is 30 ÷ 3 = 10 mg/mL. For a 2.5 mg dose: 2.5 ÷ 10 = 0.25 mL = 25 units. For a 5 mg dose: 5 ÷ 10 = 0.5 mL = 50 units.
How to Reconstitute Tirzepatide — BAC Water Ratios for 10 mg, 30 mg and 60 mg Vials
Reconstituting tirzepatide from a lyophilized vial requires choosing a BAC water volume that determines your solution's concentration — the most common choice is 2 mL of bacteriostatic water per 10 mg vial (producing a 5 mg/mL concentration), which makes dose calculation straightforward: 0.5 mL = 2.5 mg, 1.0 mL = 5 mg.
Concentration Reference Table
Vial Size | BAC Water | Concentration | Best For |
|---|---|---|---|
10 mg | 1 mL | 10 mg/mL | Experienced users wanting precise low-volume doses |
10 mg | 2 mL | 5 mg/mL | Most common — easy math, forgiving for beginners |
30 mg | 2 mL | 15 mg/mL | Higher doses with fewer draws; more vial life |
30 mg | 3 mL | 10 mg/mL | Good balance of math simplicity and dose range |
60 mg | 3 mL | 20 mg/mL | High-dose users (10+ mg); maximizes vial life |
60 mg | 6 mL | 10 mg/mL | Simple math across the full titration range |
Which volume should you choose? Less BAC water = higher concentration = fewer units per dose = more precise for low doses and more weeks per vial. More BAC water = lower concentration = easier math = more forgiving for beginners and less concentrated injections (which can reduce injection site irritation). If this is your first time reconstituting, 2 mL per 10 mg vial (5 mg/mL) is the simplest starting point.
Reconstitution Steps
The process is identical to reconstituting any lyophilized peptide:
Wipe the vial stopper with an alcohol swab. Let it dry.
Draw the selected volume of bacteriostatic water into a syringe.
Insert the needle through the stopper and inject the water slowly down the side of the vial — do not spray directly onto the powder.
Swirl gently — do NOT shake. Shaking denatures the peptide and reduces potency.
Wait until the powder is completely dissolved. The solution should be clear and colorless. Pink or red coloring indicates a B12 additive (some compounding pharmacies add methylcobalamin or cyanocobalamin) — this is not degradation. If the solution is cloudy, yellow, brown, or has particulate — discard it.
Store the reconstituted vial in the refrigerator at 2–8°C.
For the complete reconstitution technique with visual guidance, see the reconstitution guide.
Where and How to Inject Tirzepatide
Tirzepatide is injected subcutaneously once per week on the same day each week — the abdomen is the most common site (at least 2 inches from the navel), with the outer thigh and back of the upper arm as rotation alternatives — and no fasting or meal timing is required before or after injection.
Injection Sites
Abdomen: the easiest and most commonly used site. Choose a spot at least 2 inches from the navel in any direction, avoiding the midline. The abdomen provides the most consistent fat pad depth and the largest rotation area. Pinch a fold of skin horizontally and insert at 45–90 degrees.
Outer thigh: the lateral (outer) surface of the upper thigh, in the middle third between knee and hip. Sit with the leg relaxed. Pinch vertically. Leaner users should use 45 degrees to avoid reaching muscle.
Upper arm: the back/outer surface between the shoulder and elbow. Slightly harder to self-administer but a valid rotation site.
Rotate injection sites weekly. Do not inject in the exact same spot each week — this causes lipodystrophy (localized fat tissue changes from repeated needle trauma). Move to a different site or different area within the same site with each injection.
Technique Summary
Use a 29–30 gauge, 1/2 inch insulin syringe (U-100). Pinch the skin, insert the needle in a smooth dart-like motion, inject slowly over 3–5 seconds, release the skin, withdraw, and dispose in a sharps container. No aspiration needed for subcutaneous injection. For the complete step-by-step technique with angle and depth guidance, see the injection guide. For why tirzepatide uses subcutaneous rather than intramuscular injection, see the SubQ vs IM comparison.
Tirzepatide Storage — Refrigeration, Shelf Life and Expiration
Reconstituted tirzepatide should be refrigerated at 2–8°C and used within 28–56 days of mixing — and per FDA prescribing information for Zepbound, the reconstituted solution can be kept at room temperature (≤30°C) for up to 21 days if refrigeration is temporarily unavailable, though compounded tirzepatide stability data may differ.
State | Storage Temp | Duration | Notes |
|---|---|---|---|
Unreconstituted (lyophilized) | Refrigerate (2–8°C); room temp acceptable short-term | 1–2 years (manufacturer dependent) | Room temp (≤30°C) safe for shipping and short periods (weeks) |
Reconstituted (in solution) | Refrigerate at 2–8°C | 28–56 days (consult your source's stability data) | Most compounding pharmacies provide a beyond-use date |
Reconstituted, out of fridge | ≤30°C (room temp) | Up to 21 days (per Zepbound PI) | Compounded stability may differ — check with your pharmacy |
What happens if tirzepatide is not refrigerated? Potency degrades gradually — not instantly. A vial left on the counter overnight is still usable. A vial left at room temperature for a week has reduced but not eliminated potency. The degradation is progressive, not a cliff — but the further beyond storage guidelines, the less predictable the dose delivered per injection.
Does tirzepatide expire? Lyophilized (unreconstituted) peptides typically have 1–2 year shelf life when refrigerated. Reconstituted solution should be used within the recommended window (28–56 days). Using expired tirzepatide is not dangerous — the compound degrades into inactive fragments, not toxic byproducts — but potency is reduced and unpredictable.
Color check: the reconstituted solution should be clear and colorless. Pink or red coloring in compounded tirzepatide typically indicates an added B12 supplement (methylcobalamin), not degradation. Yellow, brown, or cloudy solution indicates degradation — discard it. If you're unsure about the color, contact your compounding pharmacy to confirm whether B12 was included in the formulation.
For full storage guidance across all peptides, see the peptide storage guide.
Alcohol, Diet, Surgery and Lifestyle Questions
Tirzepatide has no direct pharmacological interaction with alcohol — but it delays gastric emptying, which means alcohol may be absorbed differently than expected, GI side effects can be amplified, and most users report reduced alcohol tolerance that catches them off guard on their first drink after starting the drug.
Alcohol
There is no pharmacological contraindication between tirzepatide and alcohol at the receptor level. However, 3 practical effects change the experience:
Altered absorption. Tirzepatide delays gastric emptying (this is part of how it works — food stays in the stomach longer, producing satiety). Alcohol in a delayed-emptying stomach may be absorbed differently, and many users report feeling intoxicated faster on less alcohol than before starting tirzepatide.
Amplified GI effects. Nausea, vomiting, and diarrhea — the most common tirzepatide side effects — are worsened by alcohol, especially during the first few weeks of a new dose level. The combination of a GLP-1 agonist plus alcohol in a slowly emptying stomach is a reliable recipe for severe nausea.
Caloric impact. Alcohol is calorie-dense (~7 kcal/g) and counterproductive to weight loss goals. If the drug is suppressing your food appetite but you're consuming 500+ calories per night in drinks, the math undermines the mechanism.
Practical guidance: you can drink on tirzepatide, but expect lower tolerance, worse nausea (especially during titration), and slower weight loss. Most practitioners recommend limiting or avoiding alcohol during active dose increases.
Diet — What to Eat on Tirzepatide
No specific foods are required or prohibited. The practical recommendations are driven by tirzepatide's GI effects:
Prioritize protein. Target 1.0–1.2 g of protein per kg of body weight per day to preserve lean muscle mass during weight loss. Tirzepatide suppresses appetite broadly — if you don't prioritize protein, you'll eat less of everything, including the amino acids your body needs to maintain muscle.
Eat smaller, more frequent meals. Tirzepatide delays gastric emptying, so large meals sit in the stomach longer than normal. This produces nausea, bloating, and discomfort. Smaller portions consumed more frequently are much better tolerated.
Stay hydrated. Diarrhea and nausea — common during titration — can cause dehydration. Drink water throughout the day, not just at meals.
Eat fiber for constipation management. Constipation is a common tirzepatide side effect. Vegetables, whole grains, and adequate fiber intake help maintain bowel regularity.
Avoid greasy, high-fat meals during titration. Fat delays gastric emptying independently — combined with tirzepatide's gastric-emptying delay, high-fat meals amplify nausea.
Surgery
Tirzepatide delays gastric emptying, which creates a risk of aspiration during anesthesia (stomach contents entering the lungs while sedated). Current guidance from the American Society of Anesthesiologists recommends discussing GLP-1 agonist use with your anesthesiologist before any elective procedure. Many anesthesiologists recommend stopping tirzepatide 1–3 weeks before surgery. This is a medical decision — consult your surgical team directly.
Not Losing Weight on Tirzepatide? Troubleshooting
The 3 most common reasons tirzepatide users don't see weight loss are: still being in early titration (2.5 mg is a starting dose, not a therapeutic dose), consuming calorie-dense foods that maintain caloric surplus despite reduced appetite, and — for compounded tirzepatide specifically — underdosed vials that deliver less than the labeled amount.
1. Still in titration — not yet at therapeutic dose. The 2.5 mg starting dose is an initiation dose. Many users see minimal weight loss until reaching 5–7.5 mg. The SURMOUNT-1 trial measured outcomes at 72 weeks — not 4 weeks. Judging efficacy during the first 1-2 dose levels is premature.
2. Caloric intake — eating less volume but more density. Tirzepatide suppresses appetite, but it doesn't force a caloric deficit. If you're eating smaller amounts of calorie-dense food (sugary drinks, alcohol, fried food, processed snacks), the reduced volume may not produce a sufficient energy deficit. Track calories for a week to diagnose this.
3. Product quality (compounded tirzepatide). A vial with 60% purity delivers approximately 60% of the labeled dose per injection — effectively a sub-therapeutic protocol without the user knowing it. This is the most common reason users report: "semaglutide worked but compounded tirzepatide doesn't." The molecule is the same — but the concentration accuracy from some compounding sources is not. Verify purity through independent lab testing or cross-reference vendor claims using Peptigrity's database. See how to verify peptide quality for the full process.
4. Metabolic adaptation. Weight loss slows as the body adapts — metabolic rate decreases as body weight decreases. Increasing physical activity and maintaining high protein intake helps counter this adaptation. This is normal biology, not a sign the drug stopped working.
5. Timeline expectations. Average weight loss in SURMOUNT-1 was ~22.5% at 72 weeks — not 12 weeks. Most clinical significance appears after month 3-4 at therapeutic doses. See the peptide results timeline for the complete week-by-week breakdown.
Frequently Asked Questions
How many units is 2.5 mg of tirzepatide?
It depends on your concentration: at 5 mg/mL (10 mg vial + 2 mL BAC water): 50 units. At 10 mg/mL (30 mg vial + 3 mL): 25 units. At 15 mg/mL (30 mg vial + 2 mL): approximately 17 units. At 20 mg/mL (60 mg vial + 3 mL): approximately 13 units. There is no universal answer — you must know your reconstitution concentration. See the master conversion table above.
Can you drink alcohol on tirzepatide?
No direct drug interaction, but tirzepatide delays gastric emptying, which changes alcohol absorption. Most users report lower tolerance (feeling intoxicated on less alcohol), amplified nausea (especially during titration), and the obvious caloric counterproductivity. You can drink, but expect reduced tolerance and worse GI effects — especially during dose increases.
What happens if tirzepatide is not refrigerated?
Short-term (overnight, a few days): minimal impact — potency degrades gradually, not instantly. Per the Zepbound prescribing information, reconstituted solution is stable at room temperature (≤30°C) for up to 21 days. Long-term room temperature storage causes progressive potency loss. Not toxic, but reduced and unpredictable efficacy. If accidentally left out overnight, return to the fridge and continue using.
What is microdosing tirzepatide?
Community practice of starting below the FDA-recommended 2.5 mg — typically 1.0–1.25 mg for the first 1–2 weeks — or extending each titration step to 6–8 weeks instead of 4. This is not in the FDA prescribing information and has no clinical validation. The rationale is straightforward: lower initial dose = less GI impact during adaptation. Users who microdose typically report gentler GI adjustment but slower onset of appetite suppression.
What should I eat on tirzepatide?
No specific food requirements. Prioritize high-protein foods (target 1.0–1.2 g/kg/day to preserve lean mass), eat smaller, more frequent meals (large meals + delayed gastric emptying = nausea), stay hydrated, eat fiber for constipation management, and avoid greasy high-fat meals during titration. There is no "tirzepatide diet" — but protein-first eating habits produce the best body composition outcomes.
How long does tirzepatide take to work?
Appetite suppression begins within week 1–4 (during the 2.5 mg starting dose). Noticeable weight loss typically appears at week 4–8. Visible body composition changes emerge at week 8–16. The full therapeutic dose is not reached until week 20+ (if titrating to 15 mg). The SURMOUNT-1 trial endpoint was ~22.5% weight loss at 72 weeks — this is a long-term compound. For the complete timeline, see the peptide results timeline.
Can you switch from semaglutide to tirzepatide?
Yes — this is common clinical practice. The general approach is to switch at an equivalent dose tier rather than cold-turkey from high-dose semaglutide to low-dose tirzepatide. No published switching protocol exists — this should be practitioner-guided. Most clinicians recommend starting tirzepatide at 2.5–5 mg regardless of prior semaglutide dose, then titrating based on response. Some users report a brief GI adjustment period when switching, similar to starting a new drug. For the full comparison, see semaglutide vs tirzepatide.
Why is my tirzepatide pink or red?
Pink or red coloring typically indicates added B12 (methylcobalamin or cyanocobalamin) — some compounding pharmacies add B12 to their tirzepatide formulations as a supplement. This is not degradation and the solution is safe to use as long as it remains clear (not cloudy). Yellow, brown, or cloudy solution indicates degradation — discard it. If you're uncertain about the color, contact your compounding pharmacy to confirm whether B12 was included. See where to buy tirzepatide for verified vendors.
How long does tirzepatide stay in your system?
Tirzepatide has a half-life of approximately 5 days, meaning it takes about 5 weeks (5 half-lives) to be fully eliminated from the body after the last injection. This is relevant for surgery timing (discuss with your anesthesiologist), fertility planning, and understanding why effects continue for days after injection rather than wearing off immediately.
This article is for educational and informational purposes only and does not constitute medical advice. Tirzepatide is an FDA-approved prescription medication (Zepbound, Mounjaro) that should be used under physician supervision. Compounded tirzepatide is subject to different regulatory oversight than brand-name products. Dosing, reconstitution, and administration information applies to compounded lyophilized tirzepatide unless otherwise noted. Always consult a qualified healthcare provider before using any peptide or medication. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
